High concentrations of soluble endoglin can inhibit BMP9 signaling in non-endothelial cells

[1]  P. Knaus,et al.  FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells , 2023, Cell Communication and Signaling.

[2]  A. Berchuck,et al.  Reciprocal SOX2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer , 2022, Cell reports.

[3]  B. Liu,et al.  Crystal structures of BMPRII extracellular domain in binary and ternary receptor complexes with BMP10 , 2022, Nature Communications.

[4]  G. Blobe,et al.  TGF‐β superfamily co‐receptors in cancer , 2021, Developmental dynamics : an official publication of the American Association of Anatomists.

[5]  R. Weiskirchen,et al.  Endoglin: An ‘Accessory’ Receptor Regulating Blood Cell Development and Inflammation , 2020, International journal of molecular sciences.

[6]  A. Sundan,et al.  Receptor binding competition: A paradigm for regulating TGF-β family action. , 2020, Cytokine & growth factor reviews.

[7]  D. Brazil,et al.  Secreted BMP antagonists and their role in cancer and bone metastases. , 2020, Bone.

[8]  N. Morrell,et al.  Molecular basis of ALK1-mediated signalling by BMP9/BMP10 and their prodomain-bound forms , 2020, Nature Communications.

[9]  M. Goumans,et al.  Endoglin: Beyond the Endothelium , 2020, Biomolecules.

[10]  D. Charnock-Jones,et al.  Role of soluble endoglin in BMP9 signaling , 2019, Proceedings of the National Academy of Sciences.

[11]  P. Knaus,et al.  BMPR2 inhibits activin and BMP signaling via wild-type ALK2 , 2018, Journal of Cell Science.

[12]  D. de Sanctis,et al.  Structural Basis of the Human Endoglin-BMP9 Interaction: Insights into BMP Signaling and HHT1 , 2017, Cell reports.

[13]  A. Hinck,et al.  Structural Biology and Evolution of the TGF-β Family. , 2016, Cold Spring Harbor perspectives in biology.

[14]  K. Edlund,et al.  The protein kinase LKB1 negatively regulates bone morphogenetic protein receptor signaling , 2015, Oncotarget.

[15]  A. Waage,et al.  Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B , 2015, Cell Communication and Signaling.

[16]  S. Gräf,et al.  Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension , 2015, Nature Medicine.

[17]  C. Patterson,et al.  The role of BMPs in endothelial cell function and dysfunction , 2014, Trends in Endocrinology & Metabolism.

[18]  A. Waage,et al.  Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin , 2014, Blood Cancer Journal.

[19]  M. Alexandrakis,et al.  Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients , 2013, Hematological oncology.

[20]  S. Kumar,et al.  Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling , 2013, Oncogene.

[21]  N. Morrell,et al.  Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension , 2013, Pulmonary circulation.

[22]  K. Kario,et al.  Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases , 2012, Heart and Vessels.

[23]  A. Alegakis,et al.  Clinical significance of sCD105 in angiogenesis and disease activity in multiple myeloma. , 2012, European journal of internal medicine.

[24]  G. Brede,et al.  Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC , 2012, Leukemia.

[25]  J. Recio-Rodríguez,et al.  Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients , 2010, BMC medicine.

[26]  F. Zhan,et al.  Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. , 2008, Blood.

[27]  M. V. Dinther,et al.  BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis , 2007, Journal of Cell Science.

[28]  L. David,et al.  Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. , 2007, Blood.

[29]  T. Libermann,et al.  Soluble endoglin contributes to the pathogenesis of preeclampsia , 2006, Nature Medicine.

[30]  A. Reddi.  BMPs: from bone morphogenetic proteins to body morphogenetic proteins. , 2005, Cytokine & growth factor reviews.

[31]  A. Waage,et al.  Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells , 2004, Oncogene.

[32]  A. Philip,et al.  Endoglin Is Expressed on Human Chondrocytes and Forms a Heteromeric Complex With Betaglycan in a Ligand and Type II TGFβ Receptor Independent Manner , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  H. Steininger,et al.  Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. , 2001, The hematology journal : the official journal of the European Haematology Association.

[34]  J. Inman,et al.  Bmc Cell Biology a Rapid and Sensitive Bioassay for the Simultaneous Measurement of Multiple Bone Morphogenetic Proteins. Identification and Quantification of Bmp4, Bmp6 and Bmp9 in Bovine and Human Serum , 2022 .